Primary hyperparathyroidism

Endocrinology and Diabetes: A Problem-Oriented Approach

Volumn , Issue , 2013, Pages 279-291

  Bandeira, Francisco ^a   Amaral, Lívia ^a   Aragão, Paula ^a  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84906654723     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-8684-8_22     Document Type: Chapter

References (71)

1. Eufrazino CSS, Veras A, Bandeira F. Prevalência de hiperparatireoidismo primário em uma grande população atendida em dois centros de referência na cidade do Recife. Arq Bras Endocrinol Metabol. 2010; 54: S439.
2. Bandeira F, Griz L, Caldas G, et al. Characteristics of primary hyperparathyroidism in one institution in northeast Brazil. Bone. 1998; 23(suppl): S380.
3. Rodgers SE, Lew JI, Soló rzano CC. Primary hyperparathyroidism. Curr Opin Oncol. 2008; 20: 52-8.
4. Bilezikian JP, Brandi ML, Rubin M, Silverberg SJ. Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features. J Intern Med. 2005; 257: 6-17.
5. Brandi ML, Falchetti A. Genetics of primary hyperparathyroidism. Urol Int. 2004; 72 (Suppl 1): 11-6)
6. Simonds WF, James-Newton LA, Agarwal SK, et al. Familial isolated hyperparathyroidism: clinical and genetic characteristics of thirty-six kindreds. Medicine (Baltimore). 2002; 81: 1-26.
7. Marx SJ, Simonds SF, Agarwal SK, et al. Hyperparathyroidism in hereditary syndromes: special expressions and special managements. J Bone Miner Res. 2002; 17: 37-43.
8. Eastell R, Arnold A, Brandi ML, et al. Diagnosis of asymtomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab. 2009; 94: 340-50.
9. Andrade LD, Marques TF, Diniz ET, Lucena CS, Griz L, Banderia F. Impact of the use of hydrochlorothiazide in secretion PTH in hypertensive patients. Arq Bras Endocrinol Metabol. 2010; 54 Suppl 5: S491.
10. Jacobs TP, Bilezikian JP. Clinical review: rare causes of hypercalcemia. J Clin Endocrinol Metab. 2005; 90: 66316-22.
11. Pausova Z, Soliman E, Amizuka N, Janicic N, Konrad EM, Arnold A, et al. Role of the RET proto-oncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2. J Clin Endocrinol Metab. 1996; 81(7): 2711.
12. Feder JM, Sirrs S, Anderson D, Sharif J, Khan A. Primary hyperparathyroidism: an overview. Intern J of Endocrinol. 2011; 2011: 251410.
13. Ong GSY, Walsh JP, Stuckey BGA, Brown SJ, Rossi E, Ng JL, et al. The importance of measuring ionized calcium in characterizing calcium status and diagnosing primary hyperparathyroidism. J Clin Endocrinol Metab. 2012; 97(9): 3138-45.
14. Yu N, Donnan PT, Murphy MJ, Leese GP. Epidemiology of primary hyperparathyroidism in Tayside, Scotland, UK. Clin Endocrinol. 2009; 71: 485-93.
15. Bandeira F, Caldas G, Freese E, Griz L, Faria M, Bandeira C. Relationship between vitamin D serum status and clinical manifestations of primary hyperparathyroidism. Endocr Pract. 2002; 8: 266-70.
16. Bandeira FB, Griz L, Caldas G, Bandeira C, Freese E. From mild to severe primary hyperparathyroidism: the Brazilian experience. Arq Bras Endocrinol Metabol. 2006; 50(4): 657-63.
17. Bandeira F, Graf H, Griz L, Faria M, Lazaretti-Castro M. Endocrinologia e diabetes, vol. 37. a ed. Rio de Janeiro: Medbook; 2009. p. 385-93.
18. Carroll MF, Schade DS. A practical approach to hypercalcemia. Am Fam Physician. 2003; 67: 1959-66.
19. Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperparathyroidism. Arq Bras Endocrinol Metabol. 2010; 54(2): 106-9.
20. Guise TA, Mundy GR. Cancer and bone. Endocr Rev. 1998; 19(1): 18-54.
21. Silverberg SJ, Lewiecki EM, Mosekilde L, et al. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab. 2009; 94: 351-65.
22. Silverberg SJ, Bilezikian JP. Primary hyperparathyroidism. Endocrinology. 2001; 1075-93.
23. Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab. 2007; 92: 3001-5.
24. Marques TF, Vasconcelos R, Diniz E, Rêgo D, Griz L, Bandeira F. Normocalcemic primary hyperparathyroidism in clinical practice: an indolent condition or a silent threat. Arq Bras Endocrinol Metabol. 2011; 55(5): 314-7.
25. Tordjman KM, Greenman Y, Osher E, Shenkerman G, Sern N. Characterization of normocalcemic primary hyperparathyroidism. Am J Med. 2004; 117: 861-3.
26. Lundgren E, Hagstrom EG, Lundin J, Winnerback MB, Roos J, Ljunghall S, et al. Primary hyperparathyroidism revisited in menopausal women with serum calcium in the upper normal range at population based screening 8 yrs ago. World J Surg. 2002; 26: 931-6.
27. Silverberg SJ, Bilezikian JP. "Incipient" primary hyperparathyroidism: a "forme fruste" of an old disease. J Clin Endocrinol Metab. 2003; 88(11): 5348-52.
28. Bilezikian JP, Rubin M, Silverberg SJ. Asymptomatic primary hyperparathyroidism. Arq Bras Endocrinol Metabol. 2006; 50(4): 647-56.
29. Siilin H, Lundgren E, Mallmin H, et al. Prevalence of primary hyperparathyroidism and impact on bone mineral density in elderly men: MrOs Sweden. World J Surg. 2011; 35(6): 1266-72.
30. Rao DS, Philips ER, Divind GW, Talpos GB. Randomized controlled clinical trial of surgery versus no surgery in patients with mild PHPT. J Clin Endocrinol Metab. 2004; 89: 5415-22.
31. Tamura Y, Araki A, Chiba Y, Mori S, Hosoi T, Horiuchi T. Remarkable increase in lumbar spine bone mineral density and amelioration in biochemical markers of bone turnover after parathyroidectomy in elderly patients with primary hyperparathyroidism: a 5-year follow-up study. J Bone Miner Metab. 2007; 25: 226-31.
32. Joborn C, Hetta J, Johansson H, et al. Psychiatric morbidity in primary hyperparathyroidism. World J Surg. 1988; 12: 476-81.
33. Coker LH, Rorie K, Cantley L, Kirkland K, Stump D, Burbank N, et al. Primary hyperparathyroidism, cognition, and health-related quality of life. Ann Surg. 2005; 242(5): 642-50.
34. Walker MD, McMahon DJ, Inabnet WB, Lazar RM, Brown I, Vardy S, et al. Neuropsychological features in primary hyperparathyroidism: a prospective study. J Clin Endocrinol Metab. 2009; 94(6): 1951-8.
35. Eufrazino CSS, Bandeira F, et al. Peripheral polyneuropathy associated with primary hyperparathyroidism. Arq Bras Endocrinol Metabol. 2008; 52(6): 976.
36. Moskal W. Severe sensorimotor polyneuropathy in primary hyperparathyroidism. Neurol Neurochir Pol. 1999; 33(6): 1443-7.
37. Chou FF, Sheen-Chen SM, Leong CP. Neuromuscular recovery after parathyroidectomy in primary hyperparathyroidism. Surgery. 1995; 117(1): 18-25.
38. Hedback M, Odén S, et al. Cardiovascular disease, hypertension and renal function in primary hyperparathyroidism. J Intern Med. 2002; 251: 476-83.
39. Marcocci C, Cetani F. Primary hyperparathyroidism. N Engl J Med. 2011; 365: 2389-97.
40. Yu N, Donnan PT, Flynnt RWV, et al. Increased mortality and morbidity in mild primary hyperparathyroid patients. The parathyroid epidemiology and audit research study (PEARS). Clin Endocrinol. 2010; 73: 30-4.
41. Yu N, Donnan PT, Leeset GP. A record linkage study of outcomes in patients with mild primary hyperparathyroidism: the parathyroid epidemiology and audit research study (PEARS). Clin Endocrinol. 2011; 75: 160-76.
42. Amaral LMB, Queiroz DC, Marques TF, Mendes M, Bandeira F. Normocalcemic versus hypercalcemic primary hyperparathyroidism: more stone than bone. J Osteoporos. 2012; 2012: 128352.
43. Udelsman R, Pasieka JL, et al. Surgery for asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab. 2009; 94: 366-72.
44. Mohammadi A, Moloudi F, Ghasemi-rad M. The role of colour Doppler ultrasonography in the preoperative localization of parathyroid adenomas. Endocr J. 2012; 59(5): 375-82.
45. Bandeira FAF, Oliveira R, Griz L, Caldas G, Bandeira C. Differences in accuracy of TC 99m -Sestamibi scanning between severe and mild forms of primary hyperparathyroidism. J Nucl Med Technol. 2008; 36: 30-5.
46. Beland MD, Mayo-Smith WW, Grand DJ, Machan JT, Monchik JM. Dynamic MDCT for localization of occult parathyroid adenomas in 26 patients with primary hyperparathyroidism. AJR Am J Roentgenol. 2011; 196(1): 61-5.
47. Chazen JL, Gupta A, Dunning A, Phillps CD. Diagnostic accuracy of 4D-CT for parathyroid adenomas and hyperplasia. AJNR Am J Neuroradiol. 2012; 33(3): 429-33.
48. Carvalho JRP, Diniz ET, Marques TF, Lima TPM, Galamba L, Bandeira F. PTH measurement in the fine-needle aspirates from cervical nodules in primary hyperparathyroidism. Endocr Rev. 2011; 32: P1-251.
49. Bilezikian JP, Khan AA, Potts JT. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab. 2009; 94: 335-9.
50. Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, Siris E, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab. 2008; 93: 3462-70.
51. Bollerslev J, Jansson S, Mollerup CL, Nordenström J, Lundgren E, Tørring O, et al. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab. 2007; 92(5): 1687.
52. Zanocco K, Heller M, Sturgeon C. Cost-effectiveness of parathyroidectomy for primary hyperparathyroidism. Endocr Pract. 2011; 17(1): 69-74.
53. Slepavicius A, Beisa V, Janusonis V, Strupas K. Focused versus conventional parathyroidectomy for primary hyperparathyroidism: a prospective, randomized, blinded trial. Langenbecks Arch Surg. 2008; 393(5): 659-66.
54. Clerici T, Brandle M, Lange J, Doherty GM, Gauger PG. Impact of intraoperative parathyroid hormone monitoring on the prediction of multiglandular parathyroid disease. World J Surg. 2004; 28(2): 187-92.
55. Barczynski M, Konturek A, Cichon S, Hubalewska-Dydejczyk A, Golkowski F, et al. Intraoperative parathyroid hormone assay improves outcomes of minimally invasive parathyroidectomy mainly in patients with a presumed solitary parathyroid adenoma and missing concordance of preoperative imaging. Clin Endocrinol (Oxf). 2007; 66(6): 878-85.
56. Hwang RS, Morris LF, Ro K, Park S, Ituarte PH, Hong JC, et al. A selective, Bayesian approach to intraoperative PTH monitoring. Ann Surg. 2010; 251(6): 1122-6.
57. Bergenfelz AO, Jansson SK, Wallin GK, Mårtensson HG, Rasmussen L, Eriksson HL, et al. Impact of modern techniques on short-term outcome after surgery for primary hyperparathyroidism: a multicenter study comprising 2, 708 patients. Langenbecks Arch Surg. 2009; 394(5): 851-60.
58. Miccoli P, Berti P, Materazzi G, Ambrosini CE, Fregoli L, Donatini G. Endoscopic bilateral neck exploration versus quick intraoperative parathormone assay (qPTHa) during endoscopic parathyroidectomy: a prospective randomized trial. Surg Endosc. 2008; 22: 398-400.
59. Messa P, Alfieri C, Brezzi B. Cinacalcet: pharmacological and clinical aspects. Expert Opin Drug Metab Toxicol. 2008; 4(12): 1551-60.
60. Peacock M, Bilezikian JP, Klasssen PS, et al. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 2005; 90(1): 135-41.
61. Peacock M, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, Cheng S. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in afive-year study. J Clin Endocrinol Metab. 2009; 94(12): 4860-7.
62. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Womeńs Health Initiative randomized controlled trial. JAMA. 2002; 288(3): 321-33.
63. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Reid IR. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. Ann Intern Med. 1996; 125: 360-8.
64. Orr-Walker BJ, Evans MC, Clearwater JM, Horne A, Grey AB, Reid IR. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women. Arch Intern Med. 2000; 160: 2161-6.
65. Rubin MR, Lee KH, McMahon DJ, Silverberg SJ. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2003; 88: 1174-8.
66. Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S. Effect of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res. 2001; 16: 113-9.
67. Chow CC, Chan WB, Li JK, Chan NN, Chan MH, Ko GT. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2003; 88: 581-7.
68. Parker CR, Blackwell PJ, Fairbairn KJ, Hosking DJ. Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study. J Clin Endocrinol Metab. 2002; 87: 4482-9.
69. Hershman JM, Hassani S, Braunstein GD, Geola F, Brickman A, Seibel MJ. Bisphosphonate therapy in primary hyperparathyroidism. J Bone Miner Res. 2003; 1880: 1889.
70. Khan A, Bilezikian JP, Kung AWC, Ahmed MM, Dubois SJ, HO AY, et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004; 89(7): 3319-25.
71. Jansson S, Morgan E. Biochemical effects from treatment with biphosphonate and surgery in patients with primary hyperparathyroidism. World J Surg. 2004; 28: 1293-7.